Integrated Gut Microbiota and Metabolome Analysis Reveals the Mechanism of Xiaoai Jiedu Recipe in Ameliorating Colorectal Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Jul 10

PMID 37427121

Authors

Wenli Qiu

Hui Xie

Haibin Chen

Hongli Zhou

Zhongqiu Wang

Hongguang Zhou

Affiliations

Soon will be listed here.

Abstract

Introduction: Xiaoai Jiedu recipe (XJR), a classical prescription of traditional Chinese medicine (TCM), has been clinically proven to be effective in ameliorating colorectal cancer (CRC). However, its exact mechanism of action is still elusive, limiting its clinical application and promotion to a certain extent. This study aims to evaluate the effect of XJR on CRC and further illustrate mechanism underlying its action.

Methods: We investigated the anti-tumor efficacy of XJR and experiments. An integrated 16S rRNA gene sequencing and UPLC-MS based metabolomics approach were performed to explore possible mechanism of XJR anti-CRC on the gut microbiota and serum metabolic profiles. The correlation between altered gut microbiota and disturbed serum metabolites was investigated using Pearson's correlation analysis.

Results: XJR effectively displayed anti-CRC effect both and . The abundance of aggressive bacteria such as , and decreased, while the levels of beneficial bacteria increased (, , and ). Metabolomics analysis identified 12 potential metabolic pathways and 50 serum metabolites with different abundances possibly affected by XJR. Correlation analysis showed that the relative abundance of aggressive bacteria was positively correlated with the levels of , , , , and , which was different from the beneficial bacteria.

Discussion: The regulation of gut microbiota and related metabolites may be potential breakthrough point to elucidate the mechanism of XJR in the treatment of the CRC. The strategy employed would provide theoretical basis for clinical application of TCM.

Citing Articles

Chinese Medicine in Colorectal Cancer Treatment: From Potential Targets and Mechanisms to Clinical Application.

Guo K, Wang Z, Su X Chin J Integr Med. 2024; .

PMID: 39331211 DOI: 10.1007/s11655-024-4115-8.

Treatment of colorectal cancer by traditional Chinese medicine: prevention and treatment mechanisms.

Sun J, Wei Y, Wang J, Hou M, Su L Front Pharmacol. 2024; 15:1377592.

PMID: 38783955 PMC: 11112518. DOI: 10.3389/fphar.2024.1377592.

References

Liu L, Yang M, Dong W, Liu T, Song X, Gu Y . Gut Dysbiosis and Abnormal Bile Acid Metabolism in Colitis-Associated Cancer. Gastroenterol Res Pract. 2021; 2021:6645970. PMC: 7929689. DOI: 10.1155/2021/6645970. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Sun Q, Yang H, Liu M, Ren S, Zhao H, Ming T . Berberine suppresses colorectal cancer by regulation of Hedgehog signaling pathway activity and gut microbiota. Phytomedicine. 2022; 103:154227. DOI: 10.1016/j.phymed.2022.154227. View

Guo J, Zhang L, Shang Y, Yang X, Li J, He J . A strategy for intelligent chemical profiling-guided precise quantitation of multi-components in traditional Chinese medicine formulae-QiangHuoShengShi decoction. J Chromatogr A. 2021; 1649:462178. DOI: 10.1016/j.chroma.2021.462178. View

Dalal N, Jalandra R, Bayal N, Yadav A, Harshulika , Sharma M . Gut microbiota-derived metabolites in CRC progression and causation. J Cancer Res Clin Oncol. 2021; 147(11):3141-3155. DOI: 10.1007/s00432-021-03729-w. View

Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X . Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2011; 6(2):320-9. PMC: 3260502. DOI: 10.1038/ismej.2011.109. View

Chen F, Dai X, Zhou C, Li K, Zhang Y, Lou X . Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. Gut. 2021; 71(7):1315-1325. PMC: 9185821. DOI: 10.1136/gutjnl-2020-323476. View

Halabi I, Bejjany R, Nasr R, Mukherji D, Temraz S, Nassar F . Ascorbic Acid in Colon Cancer: From the Basic to the Clinical Applications. Int J Mol Sci. 2018; 19(9). PMC: 6164730. DOI: 10.3390/ijms19092752. View

Sang T, Qiu W, Li W, Zhou H, Chen H, Zhou H . The Relationship between Prevention and Treatment of Colorectal Cancer and Cancerous Toxin Pathogenesis Theory Basing on Gut Microbiota. Evid Based Complement Alternat Med. 2020; 2020:7162545. PMC: 7391111. DOI: 10.1155/2020/7162545. View

10.

Yu M, Jia H, Zhou C, Yang Y, Zhao Y, Yang M . Variations in gut microbiota and fecal metabolic phenotype associated with depression by 16S rRNA gene sequencing and LC/MS-based metabolomics. J Pharm Biomed Anal. 2017; 138:231-239. DOI: 10.1016/j.jpba.2017.02.008. View

11.

Canellas-Socias A, Cortina C, Hernando-Momblona X, Palomo-Ponce S, Mulholland E, Turon G . Metastatic recurrence in colorectal cancer arises from residual EMP1 cells. Nature. 2022; 611(7936):603-613. PMC: 7616986. DOI: 10.1038/s41586-022-05402-9. View

12.

Mizuno R, Kawada K, Sakai Y . Prostaglandin E2/EP Signaling in the Tumor Microenvironment of Colorectal Cancer. Int J Mol Sci. 2019; 20(24). PMC: 6940958. DOI: 10.3390/ijms20246254. View

13.

Ren C, Yang M, Yang Z . The Role of Intestinal Flora and Ethnic Differences in Colorectal Cancer Risk. Gastroenterology. 2022; 163(3):782-783. DOI: 10.1053/j.gastro.2022.05.022. View

14.

Dai Z, Ren X, Xue Y, Tian Y, He B, Xu C . Association of Dietary Intake and Biomarker of α-Linolenic Acid With Incident Colorectal Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies. Front Nutr. 2022; 9:948604. PMC: 9301188. DOI: 10.3389/fnut.2022.948604. View

15.

Qiu W, Sang T, Chen H, Zhou H, Wang Z, Zhou H . Wenzi Jiedu Recipe ameliorates colorectal cancer by remodeling the gut microbiota and tumor microenvironment. Front Oncol. 2022; 12:915498. PMC: 9541612. DOI: 10.3389/fonc.2022.915498. View

16.

Yang Y, Misra B, Liang L, Bi D, Weng W, Wu W . Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer. Theranostics. 2019; 9(14):4101-4114. PMC: 6592169. DOI: 10.7150/thno.35186. View

17.

Yuan B, Ma B, Yu J, Meng Q, Du T, Li H . Fecal Bacteria as Non-Invasive Biomarkers for Colorectal Adenocarcinoma. Front Oncol. 2021; 11:664321. PMC: 8383742. DOI: 10.3389/fonc.2021.664321. View

18.

Qiu W, Wang Z, Chen R, Shi H, Ma Y, Zhou H . Xiaoai Jiedu Recipe suppresses hepatocellular carcinogenesis through the miR-200b-3p /Notch1 axis. Cancer Manag Res. 2020; 12:11121-11131. PMC: 7646463. DOI: 10.2147/CMAR.S269991. View

19.

Zhang Z, Ghosh A, Connolly P, King P, Wilde T, Wang J . Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer. J Med Chem. 2021; 64(15):11570-11596. DOI: 10.1021/acs.jmedchem.1c00890. View

20.

Tsioulias G, Go M, Rigas B . NSAIDs and Colorectal Cancer Control: Promise and Challenges. Curr Pharmacol Rep. 2015; 1(5):295-301. PMC: 4683110. DOI: 10.1007/s40495-015-0042-x. View